Abstract Resveratrol, trans-3,5,4′-trihydroxystilbene, is a polyphenolic compound which has been reported to mimic the gene expression patterns seen in whole animals undergoing dietary restriction. The mechanism of action of resveratrol remains poorly understood, but modulation of both cellular proliferation and apoptosis has been proposed as important routes by which the molecule may exert its effects. This study reports the effects of both resveratrol and dihydroresveratrol (a primary in vivo metabolite) on the proliferative capacity of human primary fibroblasts. No generalised reduction in the growth fraction was observed when fibroblasts derived from three different tissues were treated with resveratrol at concentrations of 10 μm or less. However, concentrations above 25 μm produced a dose-dependent reduction in proliferation. This loss of the growth fraction was paralleled by an increase in the senescent fraction as determined by staining for senescence associated beta galactosidase and dose recovery studies conducted over a 7-day period. Entry into senescence in response to treatment with resveratrol could be blocked by a 30-min preincubation with the p38 MAP kinase inhibitor SB203580. No effects on proliferation were observed when cells were treated with dihydroresveratrol at concentrations of up to 100 μm.
Introduction
The putative anti-ageing properties of resveratrol (trans-3,5,4′, trihydroxystilbene) are currently attracting considerable interest within the research community. Resveratrol is a phytoalexin found in high concentrations in grapes and a variety of other plant materials (Pascual-Martí et al. 2001) . It has been reported (Pearson et al. 2008 , Barger et al. 2008 ) that supplementation of the standard diet of laboratory mice with resveratrol induces a shift in patterns of gene expression in multiple tissues that is similar to that seen when animals are subjected to dietary restriction (DR). Thus, it has been proposed that resveratrol acts in some contexts as a DR mimetic, though consistent evidence of lifespan extension using the molecule is currently lacking (Wood et al. 2004 , Howitz et al. 2003 , Valenzano et al. 2006 , Bass et al. 2007 , Pearson et al. 2008 . The effects of resveratrol have been intensively studied since its "anti-ageing" activity was first reported. However, a consensus has yet to emerge regarding either the primary mode of action of the compound or its utility.
On the basis of both in vitro and in vivo studies, resveratrol has been reported to display a wide range of activities that could potentially assist in the extension of healthy life (reviewed in Saiko et al. 2008) . The molecule can be used to block peroxide-induced damage and has been shown to be neuroprotective. It can trigger cytostasis in models of cancer, induces enzymes involved in xenobiotic metabolism and increases SirT1 activity. Unsurprisingly, many of the reported activities of resveratrol have been shown to be both concentration-dependent and cell type-specific.
Although a consensus has yet to emerge regarding which activities of resveratrol are most important, alteration of the rate of cell turnover is frequently implicated as a primary mechanism by which the molecule produces beneficial effects in mammals. The anticancer activity of resveratrol is a case in point. A reduction in tumour formation would be expected to enhance organismal lifespan and multiple tumour cell lines treated with micromolar concentrations of resveratrol respond by either apoptosis or entry into a variety of cytostatic states (Jang et al. 1997 , Rusin et al. 2009 ). However, mechanisms which ascribe a central role to the antioxidant properties of the molecule also invoke cell turnover, albeit indirectly, (since reduced levels of tissue damage would be predicted to reduce the burden on cellular repair and replacement processes).
The activity of resveratrol has been heavily studied in vivo using tumour-prone rodents and in vitro in cancer cell lines but very little work has been conducted to date on primary human cell strains. This lack of data represents a significant gap in our understanding of the anti-cancer potential of resveratrol and related molecules since selectivity against tumour cells is a highly desirable property for therapeutic compounds. Recently, we demonstrated that cultures of human vascular smooth muscle cells treated with resveratrol showed a dose-dependent decrease in their growth fraction, accompanied by a dose-dependent increase in DNA damage (Burton et al. 2007 ). Interestingly, markers of apoptosis or replicative senescence were not induced indicating that (in this cell type) resveratrol appears to induce a relatively benign cytostatic state rather than a senescent one. Studies of this type are important if a better understanding of the likely effects of resveratrol in a human context is to be obtained.
In vivo, dietary resveratrol crosses the mammalian gut well but is rapidly metabolised and thus shows very limited subsequent bioavailability in the majority of tissues. Almost no unmetabolised resveratrol is observed in human plasma, but micromolar concentrations of glucuronidated and sulphated analogues can be detected, alongside the reduced metabolite, dihydroresveratrol (Walle et al. 2004) . The effects of these metabolites have been studied to a much more limited extent than the parent compound but are of considerable relevance to researchers interested in the in vivo use of resveratrol and its analogues. Accordingly, this paper reports the effects of treatment of primary human fibroblasts with both resveratrol and dihydroresveratrol.
Methods

Materials
Resveratrol, dimethyl sulfoxide and 5% palladium on carbon were obtained from Sigma-Aldrich. Acetone, methanol, hexane and ethyl acetate were obtained from Fisher Scientific. Dichloromethane and celite were obtained from Acros Organics. The primary antibody used for immunofluorescence was anti-Ki-67 and the secondary antibody polyclonal rabbit anti-mouse immunoglobulin/FITC was obtained from Dako Cytomation. Vectashield mountant, Hematoxylin QS and Nuclear Fast Red were obtained from Vector Laboratories, the foetal calf serum (FCS), non-essential amino acids, modified Eagle's medium, penicillin and streptomycin were obtained from PAA Laboratory. The human diploid foetal lung fibroblasts (MRC5) were obtained from the Coriell institute for medical research (AG05965B). All materials were used as supplied. The identity, purity and stability (>7 days, no discernable change in spectra) in dimethyl sulphoxide of resveratrol were confirmed by proton nuclear magnetic resonance and high resolution mass spectrometry.
Methods
Synthesis of α, β-dihydroresveratrol
The synthesis of α, β-dihydroresveratrol was based on the methods of Stivala et al. (2001) and is described below. α,β-Dihydro-3,4,5-trihydroxystilbene (α,β-dihydroresveratrol) was obtained by catalytic hydrogenation of trans-resveratrol (150 mg, 0.66 mmol) with 10% Pd/C catalyst in methanol (5 ml) at room temperature under atmospheric pressure. The catalyst was removed by filtration through celite and the filtrate evaporated to give a solid residue which was purified over silica gel (7:3, hexane/ethyl acetate) to obtain a brown sticky powder (97 mg, 0.42moles, 64% 4 cells/cm 2 in Modified eagle's medium with essential and non essential amino acids, 15% FCS, 2 mM glutamine, penicillin (50 U/L), streptomycin (50 μg/L). Cells were sub-cultured every 5-10 days by standard trypsin dispersion and viable cell numbers determined by trypan blue staining. Replicative lifespan was measured in population doubling calculated using the standard formula. The fibroblasts were grown on 13 mm diameter glass coverslips at identical seeding density to the parent culture. HCA2 neonatal foreskin fibroblasts (HCA2, a gift of Jim Smith, Houston, TX, USA) and Ek1.Br human ocular keratocytes (Kipling et al. 2009 ) were cultured under identical conditions.
Where applicable, a 30-min pretreatment step with 10 μM SB203580 was included. Resveratrol (0-100 μM) or dihydroresveratrol (25-100 μM) in DMSO (Sigma) were then added for 48 h. A vehicle-only control was also included.
Determination of proliferating fraction by Ki67 staining
The proliferating fraction by Ki67 staining was determined as previously described (Burton et al. 2007 ). MRC5 cells on coverslips were washed with PBS and fixed in a 1:1 mixture of methanol and acetone for 5-10 min at room temperature. The fixed cells were incubated for 1 h at room temperature with a primary antibody raised against Ki67 (Dako M0722, mouse anti-Ki67, diluted in 1% (v/v) FCS in PBS, 1/20 dilution). The cells were then washed three times in PBS and incubated for a further hour in the dark at room temperature with a secondary antibody conjugated with FITC (Dako F0261, rabbit anti-mouse FITC, diluted using 1% (v/v) FCS in PBS, 1/20 dilution). Coverslips were washed three times in PBS and once in water to remove excess salts. They were then mounted in a DAPI-containing mountant (Vectashield) and viewed on a fluorescent microscope. Cells traversing the cell cycle showed a distinctive pattern of nuclear staining. To determine the proliferating fraction, either 400 Ki67 positive or 1,000 total nuclei were counted in random fields on each of three coverslips.
Determination of senescence-associated β-galactosidase-positive fraction MRC5 cells on cover slips were washed and fixed in 3% formaldehyde for 10 min at room temperature. The cells were washed and then incubated overnight at 37°C in a solution of 4-chloro-5-bromo-3-indolyl-β-D-galactoside in citric acid phosphate buffer containing potassium ferrocyanide (5 mM) and potassium ferricyanide (5 mM). As a positive control for β-galactosidase activity, one set of coverslips was incubated in buffer at pH 4.0. To demonstrate senescence-associated β-galactosidase, the incubation buffer pH was raised to pH 6.0. The cells were counterstained using hematoxylin QS and nuclear fast red and viewed using a light microscope. To determine the senescent fraction, 1,000 cells were counted in random fields on two separate coverslips and the positive fraction calculated.
Dose recovery study
MRC5 fibroblasts at 30 population doublings were cultured as described above and were then treated for 48 h with either 50 or 100 μM resveratrol. The growth fraction was determined by Ki67 staining was determined immediately post-treatment and the assay was repeated under subconfluent conditions 7 days after removal of the resveratrol.
Results
Resveratrol induces growth arrest and senescence in normal human fibroblasts
Treatment of three separate strains of human fibroblasts with doses of resveratrol below 25 μM produced no generalised reduction in growth fraction although treatment of Ek1.Br fibroblasts with 5 μM resveratrol produced a small but significant decline in growth (Fig. 1, p=0.0285) . Interestingly, treatment with of MRC5 fibroblasts with 10 μM resveratrol increased proliferation when compared to the 2.5 μM dose (p=0.033) although proliferation was not statistically altered compared to control values.
Treatment of all three strains of fibroblasts with resveratrol for 48 h at concentrations of 25 μM or above significantly reduced the fraction of Ki67-positive nuclei. The treated fibroblasts were enlarged and flattened compared to their untreated counterparts and bore a strong similarity to cells in a state of replicative senescence. There was no detectable apoptosis in the cultures as measured by TUNEL staining (data not shown).
In a more detailed study of a single cell strain, MRC5 fibroblasts (at 30, 42 and 56 cumulative population doublings) were treated with 25-100 μM resveratrol for 48 h. Again, pronounced changes in cellular morphology were seen and were accompanied by a significant (p<0.001, one-way ANOVA) dose dependent decrease in the culture growth fraction as assessed by Ki67 labelling (Fig. 2) . Over the same concentration range, resveratrol also induced a dosedependent increase in the fraction of fibroblasts showing detectable senescence-associated β-galactosidase (SA-β-galactosidase) activity (Fig. 3) . These data are consistent with the induction of a senescent state; however, to confirm that the growth arrest observed was permanent an additional dose recovery study was undertaken. Cultures of MRC5 fibroblasts at 30 population doublings were exposed to 50 and 100 μM resveratrol for 48 h and the growth fraction determined (Fig. 4) . Resveratrol treatment significantly 
Dihydroresveratrol does not induce senescence in MRC5 cells
In an identical manner to the experiments described above, MRC5 fibroblast cultures at three different population doubling levels were treated with 25-100 μM dihydroresveratrol for 48 h; after which the growth fraction was determined by Ki67 staining. The proliferating fraction of MRC5 cells after 48 h treatment with dihydroresveratrol did not differ significantly from vehicle only controls at any concentration assayed (Fig. 6 ).
Discussion and conclusions
Resveratrol has attracted considerable interest as an "anti-ageing" compound and has shown beneficial results in in vivo studies. The mechanisms by which resveratrol is proposed to exert its effects frequently invoke changes in the growth dynamics of cell populations. In this study, we have shown that treatment of cultures of three different strains of fibroblasts with resveratrol over the concentration range commonly used in studies on tumour cell lines (25-100 μM) produces a dose-dependent decline in the growth fraction. It is also clear based on our dose recovery experiments that cells which exit the cell cycle as a result of treatment with 50 or 100 μM resveratrol are still non-dividing at least 7 days post-treatment. Given that the average cell cycle time of early passage human fibroblasts is typically less than 17-20 h (Grove and Cristofalo 1977) , a failure of the proliferative fraction to recover after 168 h is compelling evidence for permanent arrest. Loss of the culture growth fraction is accompanied by a rapid increase in the fraction of cells displaying detectable SA-β-galactosidase activity compared to vehicle only controls. These phenotypic changes are the canonical features of cells which have entered replicative senescence.
It has been known for many years that there are subtle but significant differences in the cell cycle parameter of division competent cell populations at different population doubling levels (Grove and Cristofalo 1977 ). Accordingly, we tested the effects of resveratrol on populations of MRC5 human fibroblasts at 30, 42 and 56 population doublings. Induction of senescence occurs regardless of population doubling level and in each case the number of cells entering senescence can be substantially reduced Resveratrol Concentration Percentage positive nuclei Fig. 4 Dose recovery study of MRC5 fibroblasts exposed to high concentrations of resveratrol. Cultures of MRC5 fibroblasts at 30 population doublings were exposed to either 50 or 100 μM resveratrol for 48 h and were then allowed to recover for a 7-day period after which the growth fraction was determined by Ki67 staining under subconfluent conditions. Resveratrol treatment significantly reduced the fraction of positive nuclei at both 50 (p=0.015) and 100 μM (p=0.006). However, there was no statistically significant difference in the growth fractions before and after the recovery period by a short pretreatment with the semi-selective p38MAP kinase inhibitor SB203580. This is an important finding because whilst p38-dependent arrest has been shown to occur in some cancer cell lines it also has been shown in others that resveratrolinduced growth arrest occurs in a p38-independent manner through the generation of endogenous ceramide, a mechanism which also operates in normal cells (Ulrich et al. 2007 , Venable et al. 1995 , Venable and Yin 2009 . Our data are therefore consistent with a model (see Fig. 7 ) in which the major response to exposure to resveratrol in normal fibroblasts is a rapid, p38-dependent growth arrest similar to that seen in fibroblasts taken from patients with the accelerated ageing disease Werner's syndrome or treated with hydrogen peroxide (Davis et al. 2005 , Zdanov et al. 2006 . Rendering cells incapable of division might, under certain circumstances, be beneficial (e.g. by preventing restenosis) provided that the phenotype of the arrested cells remains benign. Unfortunately, entry into senescence in fibroblasts is frequently associated with a shift to a highly proinflammatory phenotype which has the potential to compromise the function of any tissue in which such cells accumulate (Bird et al. 2003 , Herbig et al. 2006 , Kipling et al. 2009 , Burton 2009 ). In a reconstituted human skin model, the introduction of senescent fibroblasts has been shown to induce changes reminiscent of those seen in skin from the elderly (Funk et al. 2000) . Based on resveratrol's ability to activate SirT1, Cao et al. (2009) proposed that it, and related compounds, might be useful topical agents for the prevention of skin ageing. However, in the light of our data and those of Funk et al. (2000) , we consider it more likely that the topical application of resveratrol at concentrations above 25 μM will produce deleterious changes in skin structure. We caution against any such use until more extensive tests have been performed.
An uncritical reading of our data might seem to suggest that dietary supplementation with resveratrol could trigger adverse effects through the induction of cellular senescence in a range of tissues. We consider this highly unlikely because although it is absorbed well, resveratrol taken orally is rapidly metabolised and is thus not present at detectable concentrations in plasma (Walle et al. 2004) . We tested the effects of resveratrol at very low doses and found no general evidence that resveratrol has any negative effect on the growth fraction of human fibroblasts just as we had previously observed with vascular smooth muscle cells (Burton et al. 2007 ). Thus, we do not consider it likely that induction of cellular senescence in vivo could occur through this route. Fig. 7 Simple schematic for the action of resveratrol at high doses. Resveratrol at high doses can produce growth arrest either through the elevation of intracellular ceramide and its effects on the phosphorylation status of retinoblastoma or through the activation of p38MAP kinase probably through the generation of DNA strand breaks leading to growth arrest via elevated levels of the cyclin dependent kinase inhibitor p21WAF. (Diagram summarises our own data together with that of Ulrich et al. (2007) , Venable et al. (1995) , Davis et al. (2005) and Delgado et al. (2006)) This being said, a decline in the growth fraction was noted in one cell strain (Ek1.Br) treated at a dose of 5 μM resveratrol (though not at 10 μM). Interestingly, enhanced proliferation was observed for MRC5 fibroblasts treated with 10 μM resveratrol compared to 5 μM resveratrol. In this respect, our results are in contrast with those of Giovannelli et al. (2010) who report a 'tendency' for the growth of MRC5 fibroblasts to be inhibited at this dose. No data was shown to support this but the effect was clearly sufficiently large and reproducible for the researchers to select 5 μM resveratrol as the concentration at which to conduct their subsequent studies. It would appear that at low doses, the balance between the pro-proliferative and growth suppressive effects of resveratrol may be very fine and that care must be taken when comparing low dose studies using different cell strains.
Resveratrol metabolites are detectable at relatively high concentrations in human plasma (∼2 μM, following a single 25 mg oral dose) and at least one of them (dihydroresveratrol) has been proposed to display antiproliferative effects of similar potency to resveratrol itself in SCC-9 cells (Walle et al. 2004 ). However, we synthesised pure dihydroresveratrol and found that this metabolite has no effect on the growth fraction of MRC5 fibroblasts at concentrations of up to 100 μM. Equally, the sulphated and glucuronidated metabolites of resveratrol have short residence times within cells (Henry et al. 2005; Lançon et al. 2007) , and thus seem unlikely candidates for the induction of senescence, although it is possible that they have distinct effects on population dynamics.
In conclusion, our data are not consistent with postulated models of resveratrol action that invoke alterations in cell turnover as the primary mechanism by which it mediates "anti-ageing" effects. Resveratrol concentrations in vivo simply seem to be too low for the molecule to either stimulate or inhibit proliferation, and we have shown no alteration in apoptosis rates in cells exposed to micromolar concentrations of the molecule in vitro (Burton et al. 2007 and unpublished observations) . Ford et al. have recently proposed that alterations in DNA methylation in response to very low concentrations of resveratrol may mediate some of its in vivo effects (Wakeling et al. 2009 ). This seems to us to be a plausible mechanism of action for this class of molecules and it is consistent with very recent work from Giovannelli et al. (2010) who found that chronic treatment of MRC5 fibroblasts with 5 μm resveratrol reduced senescence associated beta galactosidase staining levels without significantly increasing the maximum population doubling levels attained by the cultures. We have recently published microarray datasets for the HCA2 and Ek1.Br fibroblasts strains used in this study (Kipling et al. 2009 ) and further transcriptomic analysis following treatment with physiologically reflective levels of resveratrol and dihydroresveratrol would allow Ford's hypothesis to be tested.
